| Oncotelic Therapeutics, Inc. (OTLC) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | ||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | ||||||||||||
| Operating Cash Flow | (783,017$) | (307,022$) | (126,151$) | (166,955$) | (103,890$) | (143,198$) | (261,773$) | (231,416$) | (372,617$) | (248,850$) | (448,563$) | (251,017$) | (1,251,500$) | (1,487,684$) | (1,583,256$) | 227,466$ | 31,473$ | (944,395$) | (443,066$) | (464,229$) | (117,995$) | (40,045$) | (191,034$) | 872,099$ | (882,000$) | (793,000$) | (3,096,000$) | (3,303,000$) | |||||||||||||||||||||
| Investing Cash Flow | 6,403$ | 0$ | 0$ | ||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | (1,000$) | (1,000$) | |||||||||||||||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 462,874$ | 628,000$ | 135,000$ | 160,000$ | 41,000$ | 220,000$ | 145,000$ | 250,000$ | 275,000$ | 335,000$ | 440,000$ | 200,000$ | 1,608,200$ | 599,515$ | 2,304,541$ | 250,000$ | 70,000$ | 1,003,750$ | 375,000$ | 115,000$ | 40,000$ | 0$ | 14,839,000$ | ||||||||||||||||||||||||||
| End Cash Position | 409,000$ | 88,022$ | 79,173$ | 86,128$ | 149,018$ | 72,216$ | 188,989$ | 170,405$ | 241,452$ | 830,719$ | 474,019$ | 1,362,188$ | 660,903$ | 183,437$ | 81,964$ | 16,206$ | 84,272$ | 200,000$ | 2,498$ | 1,058,000$ | 1,966,000$ | 233,000$ | 1,115,000$ | 1,908,000$ | 5,004,000$ | 6,041,000$ | 3,535,000$ | 5,167,000$ | 7,939,000$ | 13,022,000$ | 27,285,000$ | 30,251,000$ | 33,093,000$ | 35,735,000$ | 30,031,000$ | ||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (783,017$) | (307,022$) | (126,151$) | (166,955$) | (103,890$) | (143,198$) | (261,773$) | (231,416$) | (372,617$) | (248,850$) | (448,563$) | (251,017$) | (1,251,500$) | (1,487,684$) | (1,583,256$) | 227,466$ | 31,473$ | (944,395$) | (443,066$) | (464,229$) | (117,995$) | (40,045$) | (191,034$) | 872,099$ | (882,000$) | (793,000$) | (3,096,000$) | (3,303,000$) | |||||||||||||||||||||